Scopus BioPharma Inc. Common Stock
SCPS
SCPS was delisted on the 16th of December, 2022.
19 hedge funds and large institutions have $693K invested in Scopus BioPharma Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 4 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
10% less funds holding
Funds holding: 21 → 19 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
85% less capital invested
Capital invested by funds: $4.71M → $693K (-$4.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$133K |
| 2 |
Renaissance Technologies
New York
|
+$88.4K |
| 3 |
MRCM
M&R Capital Management
Summit,
New Jersey
|
+$74.1K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20K |
| 5 |
BlackRock
New York
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.43M |
| 2 |
Two Sigma Investments
New York
|
-$50K |
| 3 |
Millennium Management
New York
|
-$44K |
| 4 |
Morgan Stanley
New York
|
-$40.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$34K |
SCPS Hedge Fund Activity: Q1 2022 in Review
19 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Scopus BioPharma Inc. Common Stock (SCPS) for Q1 2022, worth a combined $693K — down 85% from $4.71M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SCPS and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $133K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.43M sold.
- 19 institutional investors held Scopus BioPharma Inc. Common Stock (SCPS) as of Q1 2022, down from 21 in Q4 2021.
- Funds reported $693K of Scopus BioPharma Inc. Common Stock stock for Q1 2022, down 85% quarter-over-quarter.
- 3 funds opened new Scopus BioPharma Inc. Common Stock positions in Q1 2022 and 4 closed out, a net change of -1 holder.
- The largest Scopus BioPharma Inc. Common Stock buyer in Q1 2022 was Geode Capital Management, an estimated $133K added.
- The largest Scopus BioPharma Inc. Common Stock seller in Q1 2022 was Armistice Capital, an estimated $3.43M sold.
Based on aggregated 13F filings for Q1 2022.